Cornerstone Pharmaceuticals-B (02616) issued an announcementbestblackjack, reached a strategic commercialization cooperation with European pharmaceutical company Ewpharma, and awarded Ewpharma the commercialization rights of suglimab in Central and Eastern Europe. Under the Licensing and Commercialization Agreement, Ewopharma will receive the rights to commercialize suglimab in Switzerland and 18 Central and Eastern European Countries (CEEs).
Under the terms of the licensing and commercialization agreement, Cornerstone Pharmaceuticals will receive a down payment of up to US$51.3 million and subsequent registration and sales milestone payments. Cornerstone Pharmaceuticals will generate international revenue by selling products to Ewopharma and its subsidiaries. Ewopharma will be responsible for pricing, reimbursement, marketing, distribution and other related matters, while Cornerstone Pharmaceuticals will be responsible for supplying products and providing necessary training and support to relevant brands.